PDL BioPharma, Inc. (PDLI) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $2.85, down from yesterday’s close by -8.06%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.Fundamental Analysis
PDL BioPharma, Inc. (PDLI) currently trades with a market capitalization of $427.87 Million. That value represents a market adjusting for revenues that have been growing by 2.32 % on a quarterly year/year basis as of the company’s last quarterly report.
You can get a sense of how sustainable that is by a levered free cash flow of $39.33 Million over the past twelve months. Generally speaking, earnings are expected to fall in coming quarters. Analysts are forecasting earnings of $0.09 on a per share basis this quarter. Perhaps, that suggests something about why 4.77% of the outstanding share supply is held by institutional investors.
It’s important to check the technicals to get a sense of how PDLI has been acting. Looking at the stock’s movement on the chart, PDL BioPharma, Inc. recorded a 52-week high of $3.55. It is now trading 0.7% off that level. The stock is trading $2.91 its 50-day moving average by 0.06%. The stock carved out a 52-week low down at $2.15.
In recent action, PDL BioPharma, Inc. (PDLI) has made a move of -7.17% over the past month, which has come on weak relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 12.84, and it’s gotten there by action that has been less volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 11.84% with $147.62 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of PDLI.